Tonje A Aksnes

Summary

Country: Norway

Publications

  1. ncbi [Smuggling of illegal drugs by body suffers]
    Tonje Amb Aksnes
    Akuttmedisinsk avdeling, Medisinsk divisjon, Ulleval universitetssykehus, 0407 Oslo
    Tidsskr Nor Laegeforen 124:1772-3. 2004
  2. ncbi A link between hypertension and atrial fibrillation: methods of treatment and prevention
    Tonje A Aksnes
    Department of Cardiology, Oslo University Hospital, Ulleval, Oslo, Norway
    Curr Vasc Pharmacol 8:769-74. 2010
  3. ncbi Prevention of atrial fibrillation in hypertension
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    Curr Hypertens Rep 10:175-81. 2008
  4. ncbi Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade
    Tonje Amb Aksnes
    Cardiovascular and Renal Research Center, Department of Cardiology and Department of Acute Medicine, Ullevaal University Hospital, Oslo, Norway
    Blood Press 17:156-63. 2008
  5. ncbi Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial
    T A Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Hum Hypertens 22:520-7. 2008
  6. ncbi Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial)
    Tonje Amb Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiol 101:634-8. 2008
  7. ncbi Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity
    Tonje Amb Aksnes
    Department of Cardiology, Cardiovascular and Renal Research Center, Ullevaal University Hospital, N 0407 Oslo, Norway
    Metabolism 56:1470-7. 2007
  8. ncbi Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    Hypertension 50:467-73. 2007
  9. ncbi Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    J Hypertens 25:15-23. 2007
  10. ncbi Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors
    T A Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Hum Hypertens 20:860-6. 2006

Detail Information

Publications15

  1. ncbi [Smuggling of illegal drugs by body suffers]
    Tonje Amb Aksnes
    Akuttmedisinsk avdeling, Medisinsk divisjon, Ulleval universitetssykehus, 0407 Oslo
    Tidsskr Nor Laegeforen 124:1772-3. 2004
    ..Body stuffers are drug dealers or drug abusers who swallow illegal drugs in an effort to conceal evidence during an arrest or in fear of being arrested...
  2. ncbi A link between hypertension and atrial fibrillation: methods of treatment and prevention
    Tonje A Aksnes
    Department of Cardiology, Oslo University Hospital, Ulleval, Oslo, Norway
    Curr Vasc Pharmacol 8:769-74. 2010
    ....
  3. ncbi Prevention of atrial fibrillation in hypertension
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    Curr Hypertens Rep 10:175-81. 2008
    ..A few prospective studies on prevention of AF recurrence with RAS blockade have been published, and more studies are expected to be published in the near future...
  4. ncbi Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade
    Tonje Amb Aksnes
    Cardiovascular and Renal Research Center, Department of Cardiology and Department of Acute Medicine, Ullevaal University Hospital, Oslo, Norway
    Blood Press 17:156-63. 2008
    ....
  5. ncbi Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial
    T A Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Hum Hypertens 22:520-7. 2008
    ....
  6. ncbi Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial)
    Tonje Amb Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiol 101:634-8. 2008
    ..In conclusion, hypertensive patients who developed DM during the VALUE trial had more AF than did patients without DM, and this may explain some of their concomitant high risk of hospitalization for heart failure...
  7. ncbi Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity
    Tonje Amb Aksnes
    Department of Cardiology, Cardiovascular and Renal Research Center, Ullevaal University Hospital, N 0407 Oslo, Norway
    Metabolism 56:1470-7. 2007
    ..Our data do not support that effects on adipokines, inflammatory markers, and whole blood viscosity could explain improved insulin sensitivity seen on AT1-receptor blockade...
  8. ncbi Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    Hypertension 50:467-73. 2007
    ....
  9. ncbi Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    J Hypertens 25:15-23. 2007
    ..This review aims to consider the preventive effect of ARBs on new-onset atrial fibrillation observed in recent reports from these trials, and to discuss possible mechanisms of the beneficial effect of angiotensin II-receptor blockade...
  10. ncbi Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors
    T A Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Hum Hypertens 20:860-6. 2006
    ..5 mg/kg/min, P = 0.039). Thus our data suggest that angiotensin II-receptor blockade with losartan improves glucose metabolism at the cellular level beyond what can be expected by the vasodilatation and blood pressure reduction alone...
  11. ncbi The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?
    Tonje Amb Aksnes
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiovasc Drugs 6:139-47. 2006
    ..However, the key goal is still to reduce BP, and this usually requires combinations of drugs...
  12. ncbi Treatment of hypertension in diabetes: what is the best therapeutic option?
    Tonje A Aksnes
    Department of Cardiology, Oslo University Hospital, Ulleval, Oslo, Norway
    Expert Rev Cardiovasc Ther 10:727-34. 2012
    ....
  13. ncbi Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study
    Arnljot Flaa
    Department of Acute Medicine Cardiovascular and Renal Research Center, Ullevaal University Hospital, N 0407 Oslo, Norway
    Metabolism 57:1422-7. 2008
    ..These findings may provide further insights into the pathophysiologic mechanisms of insulin resistance...
  14. ncbi Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials
    Arnljot Flaa
    Ullevaal University Hospital, Department of Acute Medicine, Oslo, Norway
    Expert Rev Cardiovasc Ther 5:451-61. 2007
    ....
  15. ncbi Antihypertensive treatment and new-onset diabetes mellitus
    Tonje Amb Aksnes
    Clinica Medica, Ospedale S Gerardo, University of Milan Bicocca, Via Donizetti 106, 200 52 Monza, Italy
    Curr Hypertens Rep 7:298-303. 2005
    ....